Other substances

Darunavir

A HIV-1 protease inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Darunavir is a nonpeptidic inhibitor of human immunodeficiency virus type 1 (HIV-1) protease (NCIt).

Darunavir on DrugBank
Darunavir on PubChem
Darunavir on Wikipedia

Marketed as

DARUNAVIR; PREZISTA

CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases	in silico			Feb/18/2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico			Feb/22/2020
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial Small molecule Randomized controlled open trial	Patients	3.62	darunavir/cobicistat (800mg/150mg, qd, po.) in combination with interferon alpha inhalation (100,000 iu, tid or qid)	Oct/25/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server	in silico	4.55	Predicted to bind a SARS-CoV-2 protein structural feature.	Aug/11/2020
Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection Small molecule Critical severity Cohort study	Patients	1.78	Used in a fixed-dose with cobistat. Significant increase in survival in critically ill patients. Sample size: 14 + 28 control. Dosage: 800 mg.	Aug/27/2020
Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease 3CLpro Small molecule In silico	in silico	1.77	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Dec/11/2020

AI-suggested references

Link	Publication date
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.	Aug/18/2020
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?	Nov/30/2021
Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.	Jan/29/2021
Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies.	Sep/01/2021
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.	Aug/08/2020
Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.	Feb/20/2021
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.	Jul/02/2021
Combinatorial approach of vitamin C derivative and anti-HIV drug-darunavir against SARS-CoV-2.	Sep/06/2021
Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora.	Sep/20/2021
Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.	Jan/21/2022
Potential of Marine Terpenoids against SARS-CoV-2: An In Silico Drug Development Approach.	Oct/20/2021
Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins.	Aug/04/2021
Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach.	Nov/05/2020
Anti-HIV drug repurposing against SARS-CoV-2	Apr/21/2020
Identification of potential antivirals against SARS-CoV-2 using virtual screening method.	Feb/10/2021
Blue Biotechnology: Computational Screening of Sarcophyton Cembranoid Diterpenes for SARS-CoV-2 Main Protease Inhibition.	Jul/13/2021
Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease.	Jun/12/2020
Identification of natural inhibitors against prime targets of SARS-CoV-2 using molecular docking, molecular dynamics simulation and MM-PBSA approaches	Aug/21/2020
Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors	Nov/05/2021
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.	Oct/13/2020
Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies	Jul/30/2021
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection	Nov/23/2020
In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors	Jul/20/2020
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments	Feb/02/2021
The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults	Feb/10/2021
In silico study of natural compounds from sesame against COVID-19 by targeting Mpro, PLpro and RdRp	Jun/24/2021
Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro	Dec/02/2021
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation	Aug/03/2021
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19	Mar/04/2021
Drug repurposing and computational modeling for discovery of inhibitors of the main protease (Mpro) of SARS-CoV-2	Jul/02/2021
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.	Aug/27/2020
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19	Jun/21/2020
Data on the stability of darunavir/cobicistat suspension after tablet manipulation	Apr/12/2020
Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?	Aug/27/2021
Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations	Jun/01/2020
Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design	Dec/05/2021
Drug repurposing approach to fight COVID-19	Sep/05/2020
Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study	Jun/16/2020
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection	Nov/04/2021
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment	Oct/06/2020
Tocilizumab in HIV patient with severe COVID-19: case report	Oct/16/2021
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.	Nov/26/2020
Peptide-like and small-molecule inhibitors against Covid-19	Sep/18/2021
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study	May/04/2022
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.	Sep/21/2020
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	Feb/16/2021
A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient	Jul/10/2020
Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment	Feb/15/2021
Efficiency of antiviral treatment in COVID-19.	Apr/19/2021
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience	Jan/18/2022
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study	Jun/25/2021
Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease	May/21/2020
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition	Jan/28/2022
Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.	Apr/13/2021
Lack of antiviral activity of darunavir against SARS-CoV-2	Feb/03/2022
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19	Feb/26/2021
Synthesis of 3,3'-methylenebis(4-hydroxyquinolin-2(1H)-ones) of prospective anti-COVID-19 drugs.	Sep/14/2020
Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital.	Jul/31/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04425382	Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar	Recruiting		Mar/01/2020	Sep/01/2020
Alternative id - MRC-05-069 Interventions - Drug: Darunavir/Cobicistat\|Drug: Lopinavir/Ritonavir Study type - Observational Study results - No Results Available Locations - Hamad Medical Corporation, Doha, Qatar Study designs - Observational Model: Other\|Time Perspective: Retrospective Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint)\|Percentage of Virological Clearance\|Percentage of Clinical Deterioration\|Incidence of Adverse Events\|Length of Hospital Stay\|All-cause Mortality
NCT04252274	Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19	Recruiting	Phase 3	Jan/30/2020	Dec/31/2020
Alternative id - DC-COVID-19 Interventions - Drug: Darunavir and Cobicistat Study type - Interventional Study results - No Results Available Locations - Shanghai Public Health Clinical Center, Shanghai, Shanghai, China\|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 30 Age - Child, Adult, Older Adult Outcome measures - The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7\|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3\|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5\|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0\|The critical illness rate of subjects at weeks 2\|The mortality rate of subjects at weeks 2

Export (.csv)